Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 172

1.

Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.

Atkinson R, Mollerup J, Laenkholm AV, Verardo M, Hawes D, Commins D, Engvad B, Correa A, Ehlers CC, Nielsen KV.

Arch Pathol Lab Med. 2011 Aug;135(8):1010-6. doi: 10.5858/2010-0462-OAR.

PMID:
21809992
[PubMed - indexed for MEDLINE]
2.

Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.

Laurinaviciene A, Dasevicius D, Ostapenko V, Jarmalaite S, Lazutka J, Laurinavicius A.

Diagn Pathol. 2011 Sep 23;6:87. doi: 10.1186/1746-1596-6-87.

PMID:
21943197
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.

Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, Tse CC.

Mod Pathol. 2008 Oct;21(10):1271-7. doi: 10.1038/modpathol.2008.83. Epub 2008 May 16.

PMID:
18487992
[PubMed - indexed for MEDLINE]
Free Article
4.

HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.

Ciampa A, Xu B, Ayata G, Baiyee D, Wallace J, Wertheimer M, Edmiston K, Khan A.

Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):132-7.

PMID:
16785779
[PubMed - indexed for MEDLINE]
5.

Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.

Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V.

Arch Pathol Lab Med. 2011 Nov;135(11):1460-5. doi: 10.5858/arpa.2010-0541-OA.

PMID:
22032573
[PubMed - indexed for MEDLINE]
6.

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J.

Breast Cancer Res. 2007;9(5):R68.

PMID:
17922920
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification.

Cayre A, Mishellany F, Lagarde N, Penault-Llorca F.

Breast Cancer Res. 2007;9(5):R64.

PMID:
17908324
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.

Yosepovich A, Avivi C, Bar J, Polak-Charcon S, Mardoukh C, Barshack I.

Isr Med Assoc J. 2010 Jun;12(6):353-6.

PMID:
20928989
[PubMed - indexed for MEDLINE]
Free Article
9.

Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.

Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, Fiche M, Jacquemier J, Mathieu MC, Penault-Llorca F, Rigaud C, Roger P, Treilleux I, Vilain MO, Mathoulin-Pélissier S, Le Doussal V.

Histopathology. 2003 Apr;42(4):337-47.

PMID:
12653945
[PubMed - indexed for MEDLINE]
10.

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

Owens MA, Horten BC, Da Silva MM.

Clin Breast Cancer. 2004 Apr;5(1):63-9.

PMID:
15140287
[PubMed - indexed for MEDLINE]
11.

The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer.

Diaz LK, Gupta R, Kidwai N, Sneige N, Wiley EL.

J Histochem Cytochem. 2004 Apr;52(4):501-7.

PMID:
15034001
[PubMed - indexed for MEDLINE]
12.

An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.

O'Grady A, Allen D, Happerfield L, Johnson N, Provenzano E, Pinder SE, Tee L, Gu M, Kay EW.

Appl Immunohistochem Mol Morphol. 2010 Dec;18(6):489-93. doi: 10.1097/PAI.0b013e3181e3d893.

PMID:
20661132
[PubMed - indexed for MEDLINE]
13.

Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence in situ hybridization.

Layfield LJ, Willmore-Payne C, Isom G, Holden JA.

Appl Immunohistochem Mol Morphol. 2008 Dec;16(6):562-7. doi: 10.1097/PAI.0b013e318171923a.

PMID:
18948825
[PubMed - indexed for MEDLINE]
14.

Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.

Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, Carrier M, Huntsman D, Aparicio S.

BMC Cancer. 2009 May 29;9:165. doi: 10.1186/1471-2407-9-165.

PMID:
19476653
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.

Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M.

Clin Cancer Res. 2005 Dec 1;11(23):8348-57.

PMID:
16322295
[PubMed - indexed for MEDLINE]
Free Article
16.

Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.

Papouchado BG, Myles J, Lloyd RV, Stoler M, Oliveira AM, Downs-Kelly E, Morey A, Bilous M, Nagle R, Prescott N, Wang L, Dragovich L, McElhinny A, Garcia CF, Ranger-Moore J, Free H, Powell W, Loftus M, Pettay J, Gaire F, Roberts C, Dietel M, Roche P, Grogan T, Tubbs R.

Am J Surg Pathol. 2010 Jun;34(6):767-76. doi: 10.1097/PAS.0b013e3181d96231.

PMID:
20421783
[PubMed - indexed for MEDLINE]
17.

Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization.

Park S, Park HS, Koo JS, Yang WI, Kim SI, Park BW.

Cancer. 2012 Feb 15;118(4):914-23. doi: 10.1002/cncr.26406. Epub 2011 Jul 28.

PMID:
21800290
[PubMed - indexed for MEDLINE]
Free Article
18.

Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study.

Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B, Cummings M, Farshid G, Field A, Morey A, McKenzie P, Raymond W, Robbins P, Tan L.

Breast. 2003 Apr;12(2):92-8.

PMID:
14659337
[PubMed - indexed for MEDLINE]
19.

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.

Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Osamura RY.

BMC Cancer. 2010 Oct 7;10:534. doi: 10.1186/1471-2407-10-534.

PMID:
20925963
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

[Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].

Zeng X, Liang ZY, Wu SF, Zhou WX, Gao J, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):584-8. Chinese.

PMID:
17134563
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk